Get informed when a big investor buys or sells
+ Follow6.28%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
G&E Herbal Biotechnology , Ltd. posts a ROE of 6.28%. That is below the Healthcare sector average of 13.1%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 13.1% is typical. G&E Herbal Biotechnology , Ltd.'s 6.28% is lower that level. That is roughly 52.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
G&E Herbal Biotechnology , Ltd.'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 6.28%; use YoY and peer views to separate noise from signal.
Context for 4911.TWO's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.1%), and (3) consistency with growth and profitability. This page covers the first two; G&E Herbal Biotechnology , Ltd.'s other metric pages and overview cover the third.
Judging G&E Herbal Biotechnology , Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 6.28% here, then scan peer and history charts to see if the gap is persistent.